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Shigella sonnei UCN59, isolated during an outbreak 
of S. sonnei in January 2007, was resistant to azithromy-
cin (MIC 64 mg/L). The isolate contained a plasmid-borne 
mph(A) gene encoding a macrolide 2′-phosphotransferase 
that inactivates macrolides. Emergence of the mph(A) gene 
in S. sonnei may limit usefulness of azithromycin for treat-
ment of shigellosis.
S
higellosis remains a common gastrointestinal disease 
in developing and industrialized countries. It occurs 
mostly in children <5 years of age; Shigella sonnei is 
the most frequently isolated species (1). Ampicillin and 
trimethoprim-sulfamethoxazole alleviate the dysenteric 
syndrome of shigellosis and reduce the infectious period. 
However, current resistance patterns limit the use of these 
drugs (2). Although ﬂ  uoroquinolones are an effective al-
ternative for adults, they are not approved for shigellosis 
treatment in children <18 years of age because of their 
potential toxicity (2,3). Azithromycin, a macrolide, rep-
resents an attractive treatment option for several reasons. 
It has in vitro activity against most Shigella spp. isolates 
(4), can be given once a day, and attains high intracellular 
concentrations (5). Despite MICs from 2 to 8 mg/L for 
Shigella spp., sufﬁ  cient concentrations of azithromycin in 
the colon may inhibit Shigella spp. growth (6). Azithro-
mycin is recommended by the American Academy of 
Pediatrics for treatment of shigellosis in children, by the 
World Health Organization as a second-line treatment in 
adults, and, since June 2004, by the Agence Française de 
Sécurité Sanitaire des Produits de Santé (2,7; www.agmed.
sante.gouv.fr/htm/10/ﬁ   lcoprs/mp040601.pdf). In 1996, 
2002, 2003, and 2007, outbreaks of shigellosis caused 
by  S. sonnei resistant to ampicillin and trimethoprim-
sulfamethoxazole occurred in children in northern Paris. 
The outbreaks occurred in religious schools, similar to cy-
clic outbreaks in US Jewish schools related to secondary 
transmission (8,9).We report an outbreak of shigellosis in 
and around Paris, France, in which azithromycin failure 
was related to emergence of plasmid-mediated resistance 
to macrolides.
The Study
On January 24, 2007, S. sonnei strain UCN59 was 
isolated from a 4-year-old girl admitted to Robert Debré 
Hospital, Paris, for bloody diarrhea and fever. The strain 
was resistant to ampicillin, trimethoprim, sulfonamides, 
and cotrimoxazole but susceptible to quinolones, third-gen-
eration cephalosporins, and doxycycline according to the 
disk-diffusion technique. MICs of macrolides were mark-
edly increased for S. sonnei UCN59 compared with those 
for a susceptible control S. sonnei UCN62 (Table). From 
January to April 23, 2007, a total of 50 cases of laboratory-
conﬁ  rmed shigellosis were identiﬁ  ed. Isolates included, in 
addition to UCN59, 31 S. sonnei that had an azithromycin 
MIC >64 mg/L from 31 children <15 years of age, who had 
each been prescribed azithromycin for diarrhea. All patients 
lived in the Paris area and attended 8 religious schools.
Typing by pulsed-ﬁ   eld gel electrophoresis (PFGE) 
and repetitive sequence–based PCR (rep-PCR) by using 
the automated DiversiLab system (bioMérieux, La-Balme-
les-Grottes, France) (10) was performed on the 32 azithro-
mycin-resistant and on 11 azithromycin-susceptible (MIC 
<16 mg/L) sporadic or outbreak isolates obtained during 
1996–2007 in the Paris area. Five different PFGE patterns 
were obtained by using the enzyme BlnI. All the 2007 
outbreak isolates, including the 32 azithromycin-resistant 
isolates and 2 azithromycin-susceptible isolates, were clus-
tered into a single proﬁ  le, proﬁ  le 1 (Figure 1). The presence 
of azithromycin-susceptible isolates with proﬁ  le 1 was de-
tected among the 1996 and 2002–2006 outbreak isolates 
(data not shown), showing the persistence of this clonal 
type over 10 years in this area of Paris. Other isolates dis-
played PFGE types 2 to 5. Low diversity of PFGE proﬁ  les 
was consistent with isolation of strains in the same area and 
for most of them from the same community. Four different 
patterns with <97% similarity were distinguished by rep-
PCR (Figure 2). Again, all the 2007 azithromycin-resistant 
isolates were clustered; however, they could be distin-
guished from the 2007 azithromycin-susceptible isolates. 
In contrast to PFGE ﬁ  ndings, rep-PCR showed that isolates 
representative of the 1996, 2002, and 2003 outbreaks were 
genetically related.
The  mph(A) gene, which encodes a macrolide 2′-
phosphotransferase that inactivates macrolide antimicro-
bial drugs, was ampliﬁ  ed from S. sonnei UCN59 DNA 
by PCR (11). PCR was negative for the erm(A), erm(TR), 
erm(B), erm(C), and erm(X) methylase genes; the ere(A), 
ere(B) genes encoding esterases; the mph(B) gene encod-
ing a phosphotransferase; and the efﬂ  ux genes mef(A) and 
msr(A). Sequence of the genes that encode ribosomal struc-
tures composing the target of macrolides, rrl, rplD, and 
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The genes conferring resistance to ampicillin and eryth-
romycin were transferred en bloc by conjugation from S. 
sonnei UCN59 to a macrolide-susceptible mutant Escheri-
chia coli AG100A at a frequency of ≈10–3 per donor cell-
forming unit after the mating period. A single plasmid was 
extracted from a transconjugant E. coli AG100A/pUV21. 
After restriction analysis, its size was estimated at ≈90 kb. 
PCR experiments showed that this plasmid belonged to in-
compatibility group I (12). MICs of macrolides for E. coli 
AG100A/pUV21 conﬁ   rmed that this plasmid conferred 
cross-resistance to macrolides (Table).
EcoRI-restricted fragments of plasmid pUV21 were 
transferred to a nylon membrane and hybridized to an 
mph(A) probe. The mph(A) gene was borne by an ≈20-kb 
EcoRI fragment, conﬁ  rming that resistance to azithromycin 
was plasmid mediated.
After plasmid digestion with PstI enzyme, a DNA 
fragment that conferred resistance to erythromycin was 
cloned in plasmid pUC18 and introduced by transforma-
tion into E. coli AG100A to generate E. coli K12 AG100A/
pUC18Ωmph(A). Sequence of the inserted DNA was de-
termined. The fragment contained 4 open reading frames 
(ORFs) in the same orientation: mph(A), mrx that putative-
ly encodes a membrane protein, mphR(A) that regulates the 
expression of mph(A), and an ORF of unknown function. 
This series of ORFs was ﬂ  anked by a copy of IS26 at the 
5′ end and a copy of IS6100 at the 3′ end. BLAST analysis 
(www.ncbi.nlm.nih.gov/blast/Blast.cgi) showed that the 
nucleotide sequence was nearly identical to that of frag-
ments of plasmid pU302L from Salmonella enterica sero-
type Typhimurium (C.Y. Chen et al., unpub. data, GenBank 
accession no. NC_006816), of Shigella ﬂ  exneri transposon 
TnSF1 (J.H. Chen and J.Y. Chen, unpub. data, GenBank 
accession no. AF188331), and of plasmids pRSB101 and 
pSRB107 (13,14).
Conclusions
Few data are available on azithromycin resistance in 
Shigella spp. A recent report from Bangladesh mentioned 
that 16% of Shigella isolates were resistant to azithromycin 
and that 62% had intermediate resistance according to the 
Clinical Laboratory Standards Institute breakpoints recom-
mended for streptococci (>1 mg/L, resistant; <0.25 mg/L, 
susceptible) (15). However, the MIC90 (MIC at which 90% 
are susceptible) of 8 mg/L displayed by the microorganisms 
was within the normal range of MICs for this microorgan-
ism; no isolate had an azithromycin MIC >24 mg/L, which 
suggests that none had acquired resistance to azithromycin. 
Surveillance for resistance to azithromycin in Shigella spp. 
requires speciﬁ  c breakpoints for this species (3).
The mph(A) gene has been detected in the sequence 
of transposon TnSF1 isolated from S. ﬂ  exneri (J.H. Chen 
and J.Y. Chen JY, unpub. data, GenBank accession no. 
AF188331). The mph(A) gene was ﬁ  rst reported in an 
E. coli isolate from Japan (10). Since then, the gene has 
been found in Aeromonas hydrophila,  Pseudomonas 
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Table. Macrolide susceptibility of outbreak and control Shigella isolates and Escherichia coli constructs 
MIC, mg/L 
Strain Erythromycin Clarithromycin Azithromycin Telithromycin 
Shigella sonnei UCN 62  64 32 2 8
S. sonnei UCN 59  1,024 1,024 64 64
Escherichia  coli K12 AG100A 2 2 2 1
E. coli K12 AG100A/pUV21  512 512 8 32
E. coli K12 AG100A/pUC18:mph(A) >1,024 512 128 512
Figure 1. Pulsed-ﬁ  eld gel electrophoresis–generated dendrogram for 43 Shigella sonnei isolates obtained from sporadic or outbreak cases 
during 1996–2007 in the Paris area. Proﬁ  le 1) representative isolates from the 2007 outbreak, including 32 isolates with azithromycin MIC 
>256 mg/L by Etest and 2 isolates with azithromycin MIC <16 mg/L. Proﬁ  le 2) 6 representative isolates from sporadic cases (2003–2006) 
with azithromycin MIC <16 mg/L. Proﬁ  le 3) representative isolate Shi 03-3580 from 2003 outbreak with azithromycin MIC <16 mg/L by 
Etest. Proﬁ  le 4) representative isolate Shi 02-9633 from 2002 outbreak with azithromycin MIC <16 mg/L by Etest. Proﬁ  le 5) representative 
isolate Shi 96 1420 from 1996 outbreak with azithromycin MIC <16 mg/L by Etest.Macrolide-Resistant Shigella sonnei
spp., Stenotrophomonas spp., and a variety of enterobac-
teria (listed at http://faculty.washington.edu/marilynr/
ermweb4.pdf).
Azithromycin was used to treat shigellosis in France 
only after the release of the French recommendations in 
2004. Subsequent rapid emergence of azithromycin-resis-
tant isolates may be a limitation for the use of macrolides 
in shigellosis. Because use of azithromycin is proposed 
for treatment of shigellosis, susceptibility of the isolates to 
azithromycin should be routinely tested.
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Figure 2. Repetitive sequence–based, PCR–generated dendrogram 
for 43 Shigella sonnei isolates obtained from sporadic or outbreak 
cases during 1996–2007 in the Paris area. Isolates with >97% 
similarity were considered to be closely genetically related. Proﬁ  le 
1) representative of the 32 isolates of the 2007outbreak with 
azithromycin (MIC >256 mg/L by Etest) . Proﬁ  le 2) 1 of 6 isolates 
from sporadic cases (2003–2006) with azithromycin MIC <16 mg/L. 
Proﬁ  le 3) representative isolate Shi 03-3580 from 2003 outbreak 
with azithromycin MIC <16 mg/L by Etest. Proﬁ  le 4) representative 
isolate Shi 02-9633 from 2002 outbreak with azithromycin MIC <16 
mg/L by Etest. Proﬁ  le 5) representative isolate Shi 96 1420 from 
1996 outbreak with azithromycin MIC <16 mg/L by Etest. Proﬁ  le 6) 
isolate from 2007 with azithromycin MIC <16 mg/L by Etest; another 
AZM S 2007 isolate had an identical proﬁ  le. AZM, azithromycin; R, 
resistant; S, sensitive; Rep, repetitive sequence-based PCR.
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